Mesalazina Doc

Mesalazine, the active ingredient in Mesalazina Doc, is an aminosalicylate presented as an oral formulation for oral use. It reduces inflammation in the gastrointestinal tract and is used to manage ulcerative colitis and Crohn's disease in adult patients.

GNH USA supplies Mesalazina Doc as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU quality standards.

Mesalazine is used to treat inflammatory bowel disease by targeting intestinal inflammation.

- Ulcerative colitis: induces and maintains remission by reducing mucosal inflammation. - Crohn's disease: helps control disease activity and maintain remission in affected intestinal segments. - Mild to moderate ulcerative colitis: alleviates symptoms and promotes mucosal healing.

Mesalazine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nausea - Abdominal pain or cramping - Headache - Flatulence or bloating - Rash or mild skin irritation - Altered taste sensation

Serious or Rare Side Effects: - Acute pancreatitis - Severe allergic reactions (e.g., anaphylaxis, Stevens‑Johnson syndrome) - Blood dyscrasias such as neutropenia or agranulocytosis - Significant elevation of liver enzymes or hepatitis - Interstitial nephritis or renal impairment - Severe colitis or toxic megacolon

Before initiating therapy, clinicians should consider several safety aspects.

- Renal function: monitor in patients with pre‑existing kidney disease. - Hepatic function: assess liver enzymes prior to treatment. - Hematology: perform periodic complete blood counts to detect rare neutropenia. - Pregnancy: use only if potential benefit justifies potential risk; data are limited. - Drug interactions: review concomitant medications for possible interactions. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Mesalazine can interact with several medicines; some require avoidance while others need close monitoring.

Major Interactions (Avoid): - Azathioprine: increased risk of bone‑marrow suppression. - Methotrexate: additive hepatotoxicity. - Live vaccines: heightened risk of infection due to immunomodulation.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): may enhance anticoagulant effect. - NSAIDs: combined use can increase renal impairment risk. - Oral contraceptives: mesalazine may reduce hormonal efficacy.